Blood Glucose Monitoring Devices Market is estimated to reach USD 21.1 billion in 2029, increasing at 7.4% CAGR during 2022-2029 | Size & Growth

Blood Glucose Monitoring Devices Market

Blood Glucose Monitoring Devices Market was estimated around USD 11.9 billion in 2021 and is expected to reach USD 21.1 billion by 2029, growing at a CAGR of 7.4% over the forecast period (2022-2029).

For Additional Insights, Click to Access Complete Report - https://www.gmiresearch.com/report/global-blood-glucose-monitoring-devices-market/

The factors driving the growth of Blood Glucose Monitoring Devices Market includes increasing prevalence of diabetes around the world, growing consumption of alcoholic beverages and unhealthy food items, rising awareness amongst consumers about the benefits of using blood glucose monitoring devices and improvements in the living standards. As per the report published by International Diabetes Federation, almost 537 million people were diagnosed with diabetes in 2021, this figure is estimated to reach 783 million by the end of 2045, which will push the demand for blood glucose monitoring devices in the approaching years. Moreover, technological advancements in blood glucose monitoring devices, growing popularity of virtual clinics, increasing geriatric population, rise in the launch of innovative products and rapid urbanization, are some of the additional factors supplementing the Blood Glucose Monitoring Devices Market Growth. In addition, the increasing investments by major corporations on research and developments, rising population growth rates and growing disposable incomes, are further propelling the Blood Glucose Monitoring Devices Market size.

However, growth of the Blood Glucose Monitoring Devices Market is hindered due to low diagnosis rate of diabetes in the developing countries.

The prominent players operating in the market are Dexcom, Inc., Sanofi, F. Hoffmann-La Roche Ltd, Terumo Corporation, Nipro Diagnostics, Abbott Laboratories, ARKRAY, Inc, Medtronic, Becton and Dickinson and Company, among others.

Based on End User, the Hospitals and Clinics segment is predicted to capture the largest market share during the forecast period

As per the Blood Glucose Monitoring Devices Market Report, increase in consumer spending on the healthcare services and technological innovations in point-of-care glucose monitoring technology, are some of the factors responsible for the segment's growth.

Based on Product Type, the Blood Glucose Monitors segment is projected to expand at a remarkable CAGR over the forecast period

Continuous Blood Glucose Monitoring (CBGM), devices assist in analyzing the glucose level pattern and provides continuous and real-time blood sugar reading, after every five minutes, which is pushing growth of the segment.

Based on Region, the North American region is anticipated to hold the highest market share during the forecast period

Presence of the leading players such as Dickinson and Company, Becton, and Abbott laboratories, increase in Government's expenditure on the healthcare sector, rapid industrialization, rising population growth rates and high per capita incomes, are some of the important factors augmenting the market growth in North American region.

Key Developments

In 2022, Abbott developed new bio-wearable, which will continuously monitor the glucose level in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.
In March 2022, DexCom publicized the receipt of CE Mark for its G7 CGM system in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app.
March 2021 - F. Hoffmann-La Roche Ltd. developed Accu-Chek Instant system to connect directly with the mySugr app and provide real-time blood glucose level data.

Market Segmentation

Segmentation by Product Type

Blood Glucose Monitors
Single Point Blood Glucose Meters
Continuous Glucose Monitoring Systems
Sensors
Transmitter and Receivers
External Monitor
Glucose Monitoring Strips
Lancets

Segmentation by End User

Hospitals and Clinics
Diagnostic Centers
Home Settings

Segmentation by Region

Asia Pacific
China
Japan
India
Rest of APAC

North America
United States of America
Canada

Europe
United Kingdom
Germany
France
Spain
Rest of Europe

RoW
Brazil
South Africa
Saudi Arabia
UAE

About GMI Research

GMI Research is a market research and consulting firm which provides market insights and intelligence across 12 major sectors helping our clients in making effective investment and business decisions.

Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Email: enquiry@gmiresearch.com
Phone: Europe - +353 1 442 8820; US - +1 860 881 2270
Address: Dublin, Ireland
Website: https://www.gmiresearch.com/

Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate, Dublin D18 Y3X2, Ireland

GMI Research's leadership team with extensive experience in research and consulting together with our research and domain expertise creates a strong value proposition to create solutions that addresses our clients business problems and add significant value to long lasting relationship.

This release was published on openPR.